Mechanism of action of bucindolol in human ventricular myocardium.
The mechanism of action of the beta-receptor antagonist bucindolol was examined in human ventricular myocardium. Bucindolol was found to be a high-affinity competitive beta-blocking agent as determined by bucindolol-[125I]iodocyanopindolol (ICYP) competition curves (KI = 3.7 +/- 1.3 x 10(-9) M, n = 10). This value was in general agreement with bucindolol KB's, determined by antagonism of isoproterenol-stimulated adenylate cyclase activity (KB = 2.8 +/- 0.55 x 10(-9) M, n = 5) or isoproterenol-augmented contraction of right ventricular trabeculae (KB = 2.9 +/- 1.9 x 10(-9) M, n = 3). In contrast, the alpha 1-receptor KI, determined at bucindolol-125IBE2254 (IBE) competition binding in rat cardiac membranes, was 1.2 x 10(-7) M. Bucindolol exhibited no beta 1- or beta 2-receptor subtype selectivity as deduced from blockade of the beta-agonist-coupled adenylate cyclase system, receptor-binding studies with preparations of human ventricular myocardium with predominantly beta 1 or beta 2 receptors, or receptor-binding studies in model systems consisting of beta 1 (guinea pig myocardial membranes) or beta 2 receptors (human mononuclear and frog myocardial membranes). In membranes derived from human ventricular myocardium and human lymphocytes, bucindolol recognized a high-affinity agonist-binding site as determined by guanine nucleotide modulation of competition-binding curves. Although bucindolol has measurable intrinsic sympathomimetic activity (ISA) in some animal systems, no increase in adenylate cyclase activity or muscle contraction was detected in preparations of human heart. In conclusion, bucindolol is a high-affinity nonselective beta-receptor antagonist with no evidence of intrinsic sympathomimetic activity in human ventricular myocardium.
Hershberger
R E
RE
Cardiology Division, University of Utah Medical Center, Salt Lake City 84132.
Wynn
J R
JR
Sundberg
L
L
Bristow
M R
MR
D000262:Adenylyl Cyclases / Q000097:blood / Q000378:metabolism; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D001667:Binding, Competitive / Q000187:drug effects; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D006321:Heart / Q000187:drug effects*; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D020120:Iodocyanopindolol; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D010627:Phenethylamines / Q000494:pharmacology; D010869:Pindolol / Q000031:analogs & derivatives / Q000494:pharmacology; D011412:Propanolamines / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D044024:Tetralones
D000319:Adrenergic beta-Antagonists; D010627:Phenethylamines; D011412:Propanolamines; D011943:Receptors, Adrenergic, beta; D044024:Tetralones; C010652:BE 2254; D020120:Iodocyanopindolol; D011433:Propranolol; D010869:Pindolol; C024307:bucindolol; D000262:Adenylyl Cyclases